Loading...
XNASKURA
Market cap569mUSD
Jan 10, Last price  
7.32USD
1D
-5.91%
1Q
-60.60%
Jan 2017
24.07%
IPO
-9.29%
Name

Kura Oncology Inc

Chart & Performance

D1W1MN
XNAS:KURA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
15.78%
Rev. gr., 5y
%
Revenues
0k
Net income
-153m
L+12.17%
-33,623-19,996-22,395-22,395-27,040-27,315-11,013,000-22,625,000-27,560,000-35,434,000-60,447,000-63,140,000-89,431,000-129,908,000-136,069,000-152,631,000
CFO
-125m
L+13.41%
-31,765-21,366-19,244-19,244-22,678-24,418-2,547-17,925,000-25,349,000-28,441,000-48,655,000-54,760,000-69,830,000-104,551,000-110,062,000-124,824,000
Earnings
Feb 25, 2025

Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
URL
https://www.kuraoncology.com/
IPO date
Nov 05, 2015
Employees
133
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
166,653
140,624
Unusual Expense (Income)
NOPBT
(166,653)
(140,624)
NOPBT Margin
Operating Taxes
229
Tax Rate
NOPAT
(166,653)
(140,853)
Net income
(152,631)
12.17%
(136,069)
4.74%
Dividends
Dividend yield
Proceeds from repurchase of equity
93,577
24,721
BB yield
-8.89%
-2.97%
Debt
Debt current
3,012
2,318
Long-term debt
23,562
16,572
Deferred revenue
Other long-term liabilities
705
265
Net debt
(397,383)
(419,305)
Cash flow
Cash from operating activities
(124,824)
(110,062)
CAPEX
(168)
(626)
Cash from investing activities
15,557
32,627
Cash from financing activities
94,783
38,565
FCF
(169,123)
(138,989)
Balance
Cash
423,957
437,985
Long term investments
210
Excess cash
423,957
438,195
Stockholders' equity
(722,703)
(576,833)
Invested Capital
1,139,387
22,314
ROIC
ROCE
EV
Common stock shares outstanding
73,229
66,990
Price
14.38
15.87%
12.41
-11.36%
Market cap
1,053,033
26.67%
831,346
-10.50%
EV
655,650
412,041
EBITDA
(165,804)
(139,865)
EV/EBITDA
Interest
1,549
229
Interest/NOPBT